20.500.12556/RUL-143965 Circulating estradiol and its biologically active metabolites in endometriosis and in relation to pain symptoms Objectives: Endometriosis (EM) is an estrogen-dominant inflammatory disease linked to infertility that affects women of reproductive age. EM lesions respond to hormonal signals that regulate uterine tissue growth and trigger inflammation and pain. The objective of this study was to evaluate whether estradiol (E2) and its biologically active metabolites are differentially associated with EM given their estrogenic and non-estrogenic actions including proliferative and inflammatory properties. Design: We performed a retrospective study of 209 EM cases and 115 women without EM. Methods: Pain-related outcomes were assessed using surveys with validated scales. Preoperative serum levels of estradiol (E2) and estrone (E1), their 2-, 4- and 16- hydroxylated (OH) and methylated (MeO) derivatives (n=16) were measured by mass spectrometry. We evaluated the associations between estrogen levels and EM anatomic sites, surgical stage, risk of EM, and symptoms reported by women. Spearman correlations established the relationships between circulating steroids. Results: Of the sixteen estrogens profiled, eleven were detected above quantification limits in most individuals. Steroids were positively correlated, except 2-hydroxy 3MeO-E1 (2OH-3MeO-E1). Higher 2OH-3MeO-E1 was linked to an increased risk of EM (Odd ratio (OR)=1.91 (95%CI 1.09-3.34); P=0.025). Ovarian EM cases displayed enhanced 2-hydroxylation with higher 2MeO-E1 and 2OH-E1 levels (P< 0.009). Abdominal, pelvic and back pain symptoms were also linked to higher 2OH-3MeO-E1 levels (OR=1.86; 95%CI 1.06-3.27; P=0.032). Conclusions: The 2-hydroxylation pathway emerges as an unfavorable feature of EM, and is associated with ovarian EM and pain related outcomes. endometriosis catechol estrogens steroids endometrioza katehol estrogeni steroidi true false true Angleški jezik Slovenski jezik Članek v reviji 2023-01-24 17:05:20 2023-01-24 17:05:27 2025-08-08 13:22:19 0000-00-00 00:00:00 2023 0 0 Str. 1-13 Vol. 13 2023 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 618.1 1664-2392 10.3389/fendo.2022.1034614 136322563 fendo-13-1034614.pdf fendo-13-1034614.pdf 1 09B973BC0A2F92605E890BDC91A47141 d7e16970dfad515469306a129fbfe6b65b09c6f79951eb27ef1edae4de693ca5 ded2709e-9ca0-11ed-9c94-00155dcfd717 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=166085 https://www.frontiersin.org/articles/10.3389/fendo.2022.1034614/full 1 fe36bde0-a2cb-11ed-9c94-00155dcfd717 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=166313 Fakulteta za farmacijo Medicinska fakulteta 0 0 0